Briefs: Dr. Agarwal's Eye Hospital and Apitoria Pharma

Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA

Apitoria Pharma gets Form 483 with 10 observations from USFDA

The observations are of procedural in nature and will be responded to within the stipulated time

Aurobindo Pharma to acquire balance 49% stake in GLS Pharma

Aurobindo Pharma’s subsidiary acquires Ace Laboratories, UK

Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month

Eugia SEZ’s injectable facility gets EIR from USFDA

The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets

CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product

Briefs: Eugia Pharma Specialities and Eugia SEZ

Eugia Pharma Specialities restarts production at terminally sterilized product lines

Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides

IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China

Aurobindo Pharma’s Eugia US Manufacturing to sell business assets to Empower Clinic Services for US$ 52 million